View Author
Dugan, M.
( M. Dugan)
patient psc -833 -833 treatment myeloid leukemia leukemia cr rate hospital study survival expression myeloid blood trial university group center treatment arm induction resistance 2 treatment arms cancer phase chemotherapy multidrug cytogenetic ratio kingdom netherland psc -833 arm analysis cycle department cd 34 cells control function result hematology p-glycoprotein germany multidrug resistance number antibody oncology table randomized death event-free survival agent j clin oncol efflux 60 years sample outcome research blast diagnosis response italy protein days 1 p-gp function myeloid leukaemia canada p-gp expression arm b belgium etoposide factor daunorubicin mitoxantrone cytarabine oncology group study patients 60 years october volume effect sonneveld leukemia group b switzerland
1 Most Recent Publications
|
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
(Article)
Holt, B. van der Verhoef, G.E.G. Knauf, W.U. Dugan, M. Shepherd, J. Piccaluga, P.P. Ossenkoppele, G.J. Vellenga, E. Ferrant, A. Fey, M.F. Crump, M. Theobald, M. Sonneveld, P. Selleslag, D. Löwenberg, B. Burnett, A.K. |
2005-01-01
|
